Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal Phase 3 randomised, double-blind, active-controlled, clinical evaluating the efficacy, safety and tolerability of modified-release hydrocortisone compared with immediate-release hydrocortisone replacement therapy in participants aged 16-years and over with Congenital-adrenal-hyperplasia

Next Previous
Search
Trial Profile

A pivotal Phase 3 randomised, double-blind, active-controlled, clinical evaluating the efficacy, safety and tolerability of modified-release hydrocortisone compared with immediate-release hydrocortisone replacement therapy in participants aged 16-years and over with Congenital-adrenal-hyperplasia

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydrocortisone (Primary) ; Hydrocortisone
  • Indications Congenital adrenal hyperplasia
  • Focus Registrational; Therapeutic Use
  • Acronyms CONnECT
  • Sponsors Diurnal

    • Most Recent Events

    • 01 Jun 2022 According to the Diurnal media release, this study is being conducted under a Special Protocol Assessment (SPA) that has been agreed with the US FDA. The SPA provides agreement that the Phase 3 trial design adequately addresses objectives that would support the regulatory submission for drug approval.
    • 01 Jun 2022 According to the Diurnal media release, this pivotal study for key US and Japan markets worth together in excess of $100m per annum will recruit up to 150 subjects with CAH who will be treated for a period of 52 weeks, The study is anticipated to take up to one year to recruit all patients, with subsequent data readout anticipated in 2024.
    • 01 Jun 2022 According to the Diurnal media release, first patient has been dosed in this trial

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top